Loading...
•
Jun 30, 2022
Mersana Q2 2022 Earnings Report
Mersana reported financial results for Q2 2022 and provided a business update.
Key Takeaways
Mersana Therapeutics reported progress in 2022, including building UpRi as a potential foundational medicine in ovarian cancer, achieving key regulatory goals with XMT-1660 and XMT-2056, and entering into two new strategic partnerships with Janssen and GSK.
UpRi's advancement remains a primary focus.
Enrollment completion in UPLIFT is approaching.
Patient screening in UP-NEXT is underway.
Mersana's proprietary ADC platforms are allowing advancement of new candidates into the clinic.
Forward Guidance
Mersana anticipates receiving $100 million from GSK as consideration for entry into the option agreement and GSK’s potential exercise of its option for a license to co-develop and commercialize XMT-2056.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...